2024
EPCO-26. LONGITUDINAL SINGLE-CELL ANALYSES IDENTIFY DRIVERS OF GENETIC, EPIGENOMIC, AND CELLULAR EVOLUTION IN IDH-MUTANT GLIOMA
Johnson K, Spitzer A, Varn F, Nomura M, Garofano L, Chowdhury T, Anderson K, D’Angelo F, Bussema L, Gritsch S, Oh Y, Moon H, Paek S, Bielle F, Laurenge A, Di Stefano A, Mathon B, Picca A, Sanson M, Lipsa A, Hertel F, Zhao Z, Wang Q, Jiang T, Hermes B, Sanai N, Golebiewska A, Niclou S, Huse J, Yung W, Lasorella A, Suvà M, Iavarone A, Tirosh I, Verhaak R. EPCO-26. LONGITUDINAL SINGLE-CELL ANALYSES IDENTIFY DRIVERS OF GENETIC, EPIGENOMIC, AND CELLULAR EVOLUTION IN IDH-MUTANT GLIOMA. Neuro-Oncology 2024, 26: viii6-viii7. PMCID: PMC11552777, DOI: 10.1093/neuonc/noae165.0025.Peer-Reviewed Original ResearchIDH-mutant gliomasGenetic alterationsStem-like populationDifferentially accessible peaksChromatin accessibility dataCopy number alterationsCellular hierarchyCycling populationTumor microenvironment cell typesSingle nucleus RNA sequencingCell cycle alterationsMalignant cell differentiationHigh tumor gradeNucleus RNA sequencingDNA sequencesATAC sequencingGenetic analysisCellular statesAccessibility peaksMicroenvironment cell typesReduced differentiationRNA sequencingIntratumoral cellular heterogeneityCellular heterogeneityTumor gradeDevelopment of Ligands and Degraders Targeting MAGE-A3
Li K, Krone M, Butrin A, Bond M, Linhares B, Crews C. Development of Ligands and Degraders Targeting MAGE-A3. Journal Of The American Chemical Society 2024, 146: 24884-24891. PMID: 39190582, DOI: 10.1021/jacs.4c05393.Peer-Reviewed Original ResearchDNA-encoded librariesSmall molecule ligandsDevelopment of ligandsE3 ligase complexCocrystal structureChemical matterLigandPROTAC moleculesSmall moleculesLigase complexTargeted Protein DegradationMAGE-A3Substrate recognition moduleType I MAGEsRING E3 ligasesMoleculesCancer-selective expressionDimer interfaceImprove immunotherapy outcomesIncreased antigen presentationHigh tumor gradeE3 ligaseComplexBiochemical functionsCancer cell surfaceInternal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial
Piltin M, Norwood P, Ladores V, Mukhtar R, Sauder C, Golshan M, Tchou J, Rao R, Lee M, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman L, Boughey J. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Annals Of Surgical Oncology 2024, 31: 7420-7428. PMID: 38980586, PMCID: PMC12101455, DOI: 10.1245/s10434-024-15708-9.Peer-Reviewed Original ResearchPathological complete responseEvent-free survivalPatients treated with neoadjuvant chemotherapyNeoadjuvant chemotherapyDistant recurrenceLocoregional recurrenceOncological outcomesClinical trialsRate of locoregional recurrenceResponse to neoadjuvant chemotherapyInternal mammary lymphadenopathyModern neoadjuvant chemotherapyHigh tumor gradeMethodsWe evaluated patientsBreast cancer stageAxillary surgeryComplete responseMedian followTumor gradePretreatment imagingLarger tumorsPrognostic indicatorI-SPY2Comparing PatientsCancer stage
2023
The clinical and genomic features of seizures in meningiomas
Dincer A, Jalal M, Gupte T, Vetsa S, Vasandani S, Yalcin K, Marianayagam N, Blondin N, Corbin Z, McGuone D, Fulbright R, Erson-Omay Z, Günel M, Moliterno J. The clinical and genomic features of seizures in meningiomas. Neuro-Oncology Advances 2023, 5: i49-i57. PMID: 37287582, PMCID: PMC10243847, DOI: 10.1093/noajnl/vdac110.Peer-Reviewed Original ResearchPeritumoral brain edemaPostoperative seizuresBrain invasionSubtotal resectionBrain edemaLarge residual tumor volumeCentral nervous system tumorsCommon central nervous system tumorPersistent postoperative seizuresResidual tumor volumeHistory of seizuresHigh tumor gradeNervous system tumorsQuality of lifePreoperative seizuresAtypical histologyMost patientsSurgical resectionCortical hyperexcitabilityUncontrolled seizuresAggressive featuresSeizure activityEpileptogenic focusCortical irritationRisk factors
2021
Hepatocellular Carcinoma
Jain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma. American Journal Of Clinical Pathology 2021, 157: 305-313. PMID: 34542582, PMCID: PMC12096300, DOI: 10.1093/ajcp/aqab125.Peer-Reviewed Original ResearchConceptsAnaplastic tumor cellsHepatocellular carcinomaNoncirrhotic liverVascular invasionHistologic patternCirrhotic liverTumor cellsClear cell subtypePathogenesis of HCCHigh histologic gradeLarger tumor sizeHigher tumor stageHigh tumor gradeHigh rateHepatitis BHepatitis CLiver diseaseTumor sizeHistologic gradeTumor stageTumor gradePathologic differencesHCC casesRetrospective analysisPathology archivesOutcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis
Li AX, Resio BJ, Canavan ME, Papageorge M, Boffa DJ, Blasberg JD. Outcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis. Journal Of Thoracic Disease 2021, 0: 0-0. PMID: 34277037, PMCID: PMC8264694, DOI: 10.21037/jtd-21-1.Peer-Reviewed Original ResearchPrimary lung sarcomaNational Cancer DatabaseLung sarcomaOverall survivalSurgical resectionMultivariable Cox proportional hazards modelsNon-small cell lung cancer patientsNational Cancer Database AnalysisCell lung cancer patientsCox proportional hazards modelCharlson-Deyo scoreFive-year OSMultivariable Cox modelPositive lymph nodesMajority of patientsLung cancer patientsHigh tumor gradeHigh-grade tumorsDifferent histologic subtypesProportional hazards modelAdjuvant chemotherapyParenchymal resectionPulmonary malignancyWorse survivalAdjusted mortality
2020
Paget disease of the breast: A national retrospective analysis of the US population
Sisti A, Huayllani MT, Restrepo DJ, Boczar D, Advani P, Lu X, Spaulding AC, Ball CT, McLaughlin SA, Forte AJ. Paget disease of the breast: A national retrospective analysis of the US population. Breast Disease 2020, 39: 119-126. PMID: 32390594, DOI: 10.3233/bd-200439.Peer-Reviewed Original ResearchConceptsNational Cancer DatabasePaget's diseaseComplete mastectomyPartial mastectomyCommon treatmentSurvival rateRegional lymph node metastasisBlack race/ethnicityHigher cancer stageNational retrospective analysisOverall survival rateLymph node metastasisLarger tumor sizeHigh tumor gradeRace/ethnicityMedian ageNode metastasisFemale patientsShorter survivalTumor sizeCancer DatabaseCancer stageTumor gradeTreatment characteristicsMetastatic cancer
2018
Pediatric Salivary Cancer: Epidemiology, Treatment Trends, and Association of Treatment Modality with Survival
Morse E, Fujiwara RJT, Husain Z, Judson B, Mehra S. Pediatric Salivary Cancer: Epidemiology, Treatment Trends, and Association of Treatment Modality with Survival. Otolaryngology 2018, 159: 553-563. PMID: 29688836, DOI: 10.1177/0194599818771926.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBiopsy, NeedleCarcinoma, MucoepidermoidChemotherapy, AdjuvantChildChild, PreschoolCombined Modality TherapyCross-Sectional StudiesDatabases, FactualFemaleHumansImmunohistochemistryLogistic ModelsMaleMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingPrognosisProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalivary Gland NeoplasmsSurvival AnalysisTreatment OutcomeConceptsImproved overall survivalOverall survivalHigh tumor gradeTreatment modalitiesTumor gradeSalivary cancerAdjuvant radiationMultivariable Cox proportional hazards regressionNational Cancer Database 2004Cox proportional hazards regressionTreatment factorsPatients 19 yearsHigh-risk patientsSubset of patientsMultivariable logistic regressionProportional hazards regressionUS national databaseHigh-grade tumorsSalivary gland cancerAcinar cell carcinomaPediatric patientsTumor characteristicsHazards regressionCell carcinomaGland cancerPrimary Salivary Type Lung Cancers in the National Cancer Database
Resio BJ, Chiu AS, Hoag J, Dhanasopon AP, Blasberg JD, Boffa DJ. Primary Salivary Type Lung Cancers in the National Cancer Database. The Annals Of Thoracic Surgery 2018, 105: 1633-1639. PMID: 29486180, DOI: 10.1016/j.athoracsur.2018.01.055.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Adenoid CysticCarcinoma, MucoepidermoidConfidence IntervalsDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPneumonectomyProportional Hazards ModelsRetrospective StudiesRisk AssessmentSalivary Gland NeoplasmsSurvival AnalysisConceptsNational Cancer DatabaseAdenoid cystic carcinomaMucoepidermoid carcinomaLung cancerCancer DatabaseMEC patientsACC patientsMortality riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelProportional hazards regression modelsAdjusted mortality riskPulmonary mucoepidermoid carcinomaLymph node metastasisPrimary lung tumorsIncomplete tumor resectionRisk of deathHazards regression modelsHigh tumor gradeOverall prognosisPrimary lungPulmonary malignancyWedge resectionNode metastasisDistant metastasis
2017
Predictors of Nonadherence to NCCN Guideline Recommendations for the Management of Stage I Anal Canal Cancer.
Kole AJ, Stahl JM, Park HS, Khan SA, Johung KL. Predictors of Nonadherence to NCCN Guideline Recommendations for the Management of Stage I Anal Canal Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 355-362. PMID: 28275036, DOI: 10.6004/jnccn.2017.0035.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAnus NeoplasmsCombined Modality TherapyDatabases, FactualDisease ManagementFemaleHumansMaleMedication AdherenceMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPractice Guidelines as TopicPrognosisProportional Hazards ModelsRisk FactorsTreatment OutcomeConceptsAnal canal cancerAnal cancerNCCN recommendationsSurgical proceduresNCCN Clinical Practice GuidelinesNational Cancer Data BaseGuideline-discordant careAnal canal carcinomaPredictors of nonadherenceClinical practice guidelinesHigh tumor gradeLow-grade tumorsLogistic regression modelingNon-academic facilitiesChi-square testDefinitive chemoradiotherapyGuideline concordantConcurrent chemoradiotherapyAnal carcinomaStandard therapyClinicopathologic factorsGuideline recommendationsMultivariable analysisMale sexTumor size
2015
Predicting pulmonary metastases among patients with indeterminate pulmonary nodules with renal cell carcinoma.
Adibi M, Kenney P, Thomas A, Devine C, Karam J, Wood C. Predicting pulmonary metastases among patients with indeterminate pulmonary nodules with renal cell carcinoma. Journal Of Clinical Oncology 2015, 33: 505-505. DOI: 10.1200/jco.2015.33.7_suppl.505.Peer-Reviewed Original ResearchIndeterminate pulmonary nodulesPulmonary metastasesChest CTTumor thrombusFat invasionLung metastasesTumor gradePulmonary nodulesRenal cell carcinoma patientsRenal sinus fat invasionRadical nephrectomy patientsRenal tumor diameterCancer-specific mortalityCell carcinoma patientsSinus fat invasionHigh tumor gradeLung metastasis developmentRenal cell carcinomaNephrectomy patientsHilar lymphadenopathyPerformance statusCarcinoma patientsIndependent predictorsSmoking statusTumor diameterNeoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database
Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR. Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database. Journal Of The American College Of Surgeons 2015, 220: 1063-1069. PMID: 25868410, DOI: 10.1016/j.jamcollsurg.2015.02.011.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseNeoadjuvant chemotherapyBreast preservationBreast conservationTumor sizeCancer DatabaseDefinitive breast surgerySmall institutional seriesBreast cancer increasesAdvanced nodal diseaseInvasive breast cancerYounger patient ageBreast tumor sizeLarger tumor sizeMultivariate logistic regressionHigh tumor gradeAmerican Cancer SocietyAdjuvant chemotherapyNodal diseasePrimary surgeryT4 tumorsInstitutional seriesPatient ageRetrospective reviewDistant metastasisGrowing Use of Mastectomy for Ductal Carcinoma-In Situ of the Breast Among Young Women in the United States
Rutter CE, Park HS, Killelea BK, Evans SB. Growing Use of Mastectomy for Ductal Carcinoma-In Situ of the Breast Among Young Women in the United States. Annals Of Surgical Oncology 2015, 22: 2378-2386. PMID: 25564175, DOI: 10.1245/s10434-014-4334-x.Peer-Reviewed Original ResearchConceptsContralateral prophylactic mastectomyUse of mastectomyYounger patientsHigh-risk histopathologic featuresNational Cancer Data BaseGreater medical comorbidityRate of mastectomyYounger patient ageBreast conservation therapyMultivariable logistic regressionHigh tumor gradeProportion of womenBackgroundDuctal carcinomaPreinvasive formExtensive diseaseMastectomy ratesMedical comorbiditiesPatient ageConservation therapyDuctal carcinomaHistopathologic featuresExcellent outcomesProphylactic mastectomySurgical choiceTumor grade
2013
Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors
Hunter K, Palermo C, Kester J, Simpson K, Li J, Tang L, Klimstra D, Vlodavsky I, Joyce J. Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors. Oncogene 2013, 33: 1799-1808. PMID: 23644656, DOI: 10.1038/onc.2013.142.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDisease ProgressionFemaleFlow CytometryGlucuronidaseGTPase-Activating ProteinsHeparan Sulfate ProteoglycansHumansImmunohistochemistryLymphangiogenesisMacrophagesMaleMiceMice, Inbred C57BLMice, TransgenicNeoplasm InvasivenessNeovascularization, PathologicNeuroendocrine TumorsPancreatic NeoplasmsConceptsPancreatic neuroendocrine tumorsRIP1-Tag2PanNET patientsNeuroendocrine tumorsTumor invasionPresence of distant metastasesHuman pancreatic neuroendocrine tumorsHeparanase levelsRIP1-Tag2 modelMouse models of cancerHigh tumor gradeAdvanced tumor stageLymphangiogenesis in vivoSpontaneous mouse modelModels of cancerPromote tumor invasionDistant metastasisTumor gradeTumor stageTumor microenvironmentPotential therapeutic targetPericyte coverageIncreased angiogenesisPanNETsMouse model
2012
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma
Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, Romani C, Todeschini P, Bandiera E, Tassi RA, Facchetti F, Sartori E, Pecorelli S, Roque DM, Santin AD. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clinical Pathology 2012, 12: 22. PMID: 23151048, PMCID: PMC3534488, DOI: 10.1186/1472-6890-12-22.Peer-Reviewed Original ResearchDisease-free survivalEndometrioid endometrial carcinomaTrop-2 overexpressionProgression-free survivalIndependent prognostic factorHigh tumor gradePrognostic factorsEndometrial carcinomaTumor gradeMultivariate analysisTrop-2 protein expressionPoor disease-free survivalReduced disease-free survivalProtein expressionAdvanced FIGO stageCommon gynecologic malignancyEndometrioid endometrial cancerLymphovascular space invasionProtein overexpressionParaffin-embedded specimensAggressive tumor phenotypeSurgical stagingCervical involvementMedical comorbiditiesEndometrial cancerPrognostic Factors and Survival in Pediatric and Adolescent Liposarcoma
Stanelle EJ, Christison-Lagay ER, Sidebotham EL, Singer S, Antonescu CR, Meyers PA, La Quaglia MP. Prognostic Factors and Survival in Pediatric and Adolescent Liposarcoma. Sarcoma 2012, 2012: 870910. PMID: 22991488, PMCID: PMC3443598, DOI: 10.1155/2012/870910.Peer-Reviewed Original ResearchOverall survivalMargin statusPediatric patientsPrognostic factorsHistologic subtypeTumor gradeFive-year overall survivalMemorial Sloan-Kettering Cancer CenterPositive surgical marginsHigh tumor gradeMedian followAdjuvant therapyRecurrent diseasePeripheral tumorsMedian ageSurgical marginsPediatric populationCentral diseaseCentral tumorsPeripheral lesionsCancer CenterPrimary tumorTumor locationPoor survivalTreatment outcomes
2010
Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer
Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. Journal Of Clinical Oncology 2010, 28: 1821-1828. PMID: 20231683, PMCID: PMC2860366, DOI: 10.1200/jco.2009.25.3286.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsBridged-Ring CompoundsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantDisease ProgressionFemaleHumansMiddle AgedNeoadjuvant TherapyReceptors, EstrogenReceptors, ProgesteroneSurvival RateTaxoidsTreatment OutcomeYoung AdultConceptsHigh Ki-67 scoreNeoadjuvant chemotherapyKi-67 scoreStable diseaseBreast cancerEstrogen receptorMultivariate analysisDistant disease-free survivalER/PR negativityFirst-line surgical approachTumor progressionMost breast cancer patientsDisease-free survivalStandard neoadjuvant chemotherapyCancer clinical stageAmerican Joint CommitteeBreast cancer patientsAfrican American raceAdvanced tumor stagePredictors of responseHigh nuclear gradeHigh tumor gradeNegative estrogen receptorNovel molecular predictorsPR negativityHistopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas
Poultsides GA, Reddy S, Cameron JL, Hruban RH, Pawlik TM, Ahuja N, Jain A, Edil BH, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL. Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas. Annals Of Surgery 2010, 251: 470-476. PMID: 20142731, PMCID: PMC3437748, DOI: 10.1097/sla.0b013e3181cf8a19.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmPancreatic ductal adenocarcinomaResection of IPMNsAdverse pathologic characteristicsInvasive pancreatic adenocarcinomaAdvanced T stageLymph node metastasisInvasive adenocarcinomaPancreatic adenocarcinomaFavorable survivalNode metastasisPathologic characteristicsT stageVascular invasionRegional lymph node metastasisFavorable biologic behaviorMicroscopic margin involvementPancreatic resection databasePositive resection marginsCox regression analysisHigh tumor gradePapillary mucinous neoplasmPoor tumor differentiationCurative intentMargin involvement
2009
Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study.
Collins L, Collins L, Gelber S, Gelber S, Ruddy K, Ruddy K, Tamimi R, Tamimi R, Come S, Come S, Marotti J, Marotti J, Schapira L, Schapira L, Kereakoglow S, Brachtel E, Brachtel E, Winer E, Winer E, Partridge A, Partridge A. Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study. Cancer Research 2009, 69: 6007-6007. DOI: 10.1158/0008-5472.sabcs-09-6007.Peer-Reviewed Original ResearchYoung Women's Breast Cancer StudyBreast Cancer StudyPoor prognostic featuresBasal-like carcinomasPathologic featuresBreast cancerYoung womenHER2 positivityPrognostic featuresTumor stageTumor necrosisER/PR negativityMulti-center prospective cohortInvasive breast cancerClinico-pathologic featuresHER2-positive tumorsCancer studiesHigh tumor gradeHigher tumor stageHigh-grade tumorsBasal-like phenotypeBiomarker expression patternsLogistic regression modelsPR negativityClinical characteristicsPredictors of tumor progression during neoadjuvant chemotherapy in breast cancer
Caudle A, Gonzalez-Angulo A, Kelly H, Liu P, Pusztai L, Symmans W, Kuerer H, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2009, 27: 603-603. DOI: 10.1200/jco.2009.27.15_suppl.603.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyHigh Ki-67High tumor gradeStable diseasePR statusBreast cancerTumor gradeKi-67Negative ERNegative ER/PR statusFirst-line surgical approachSingle comprehensive cancer centerTumor progressionER/PR statusTaxane-based regimensComplete pathologic responseSubset of patientsLymph node metastasisHigher T stageComprehensive cancer centerPre-treatment characteristicsNCT regimenLymphovascular invasionMost patientsPathologic response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply